NCT05465954View on ClinicalTrials.gov

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 24, 2023

Primary Completion Date

October 15, 2027

Study Completion Date

October 15, 2028

Conditions
High Grade Astrocytic TumorRecurrent Glioblastoma, IDH-WildtypeRecurrent Gliosarcoma
Interventions
PROCEDURE

Biospecimen Collection

Correlative studies

BIOLOGICAL

Efineptakin alfa

Given IM

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Biopsy

Undergo tumor biopsy

Trial Locations (1)

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

NeoImmuneTech
All Listed Sponsors
collaborator

NeoImmuneTech

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER